7/104 sources · 3 publishersUpdated Oct 10, 21:14 UTC
JP Morgan lifts Pfizer price target to $30 while keeping a Hold rating
JP Morgan maintained its Neutral/Hold rating on Pfizer and raised its price target from $28 to $30. The stock was trading around $27.82 at the time. The firm cited ongoing cost restructuring and pipeline renewal as reasons for the modestly higher target. Other analysts also kept Hold or Buy ratings, and Pfizer reported Q2 revenue of $15.03 billion with a net loss of $246 million.
Why it matters
JP Morgan’s higher target may support modest upside for investors, while the unchanged rating signals no shift in the firm’s overall stance. The Q2 loss highlights short‑term earnings pressure.
Key facts
- 1JP Morgan raised its price target on Pfizer to $30 from $28. marketscreener.com
- 2JP Morgan maintained a Neutral rating on Pfizer. marketscreener.com
- 3JP Morgan kept a Hold rating on Pfizer. theglobeandmail.com
- 4Pfizer’s stock was trading at $27.82. marketscreener.com
- 5Pfizer reported Q2 revenue of $15.03 billion. theglobeandmail.com
- 6Pfizer reported a Q2 net loss of $246 million. theglobeandmail.com
Summary written by AlphAI AI Desk from 4 of 4 sources. Not investment advice. Figures are as stated by the linked sources.